ASX 200·· All Ords·· Small Ords·· Resources··
Markets Methodology The Jones Report FTA Log in
Financial Trends Australia DXB ASX · Health Care LastA$0.24 JDS 88.5 A360 61.6
Health Care ASX: DXB Australia LIVE

Dimerix Ltd

PriceA$0.24
Mkt capA$140m
1Y return-56.0%
52-week range
A$0.16A$0.67
Jones Dynamic ScoreVery Strong
88.5+5.6 since 13 Jul
α
Alpha360 ScoreModerate
61.6
The Jones Nebula

Eight Alpha360 factors, each scored 0 to 100 against every listed stock worldwide. The shape is the investment case at a glance. Understand the scores →

Valuation 96.8 Growth 99.2 Cap. Market Perf. 32.4 Financial Strength 90.5 Earnings Perf. 72.2 Operating Eff. 40.6 Cash Flow Perf. 78
Valuation 96.8 Growth 99.2 Cap. Market Perf. 32.4 Financial Strength 90.5 Earnings Perf. 72.2 Operating Eff. 40.6 Cash Flow Perf. 78

The Jones Overview

Dimerix (ASX: DXB) is a high-stakes, single-asset biotech company whose survival hinges on a single drug candidate: DMX-200. While marketing materials highlight a proprietary drug-discovery platform, the reality is that almost all capital is funneled into a single global Phase 3 trial for Focal Segmental Glomerulosclerosis (FSGS), a rare and aggressive kidney disease with no current cure. The company keeps the lights on by selling off regional licensing rights for upfront cash to fund these trials, but the bulk of its headline-grabbing "$1.9 billion in milestones" is completely back-ended. Ultimately, DXB is a classic binary biotech play: if the upcoming trial data satisfies the FDA, the stock faces a massive re-rating; if the trial fails, the company has no fallback revenue to support its valuation.

What is DXB's share price doing?

1D+2.2% 1W-4.2% 1M+4.6% 3M-39.5% 6M-56.6% 1Y-56.6% 3Y+206.7% 5Y-2.5% ALL-81.6%

How does Dimerix Ltd score on Alpha360?

The eight tabs below are the Alpha360 factor scores. Built on decades of academic research, Alpha360 grades Dimerix Ltd from 0 to 100 on each dimension against all listed stocks worldwide, so a reading in the 90s is genuinely top-tier rather than a pass mark, and the Jones Dynamic Score blends all eight into a single number. Each tab gives the score, a read of what it looks like in practice, and the numbers beneath it. Data updated 19 July 2026. General information only. Some metrics via Yahoo Finance where our feed is unavailable.

Valuation
96.8
Elite

The Alpha360 valuation score weighs price against earnings, book value, cash flow and sales, ranked against all listed stocks worldwide. Dimerix Ltd scores highly on the valuation factor, but with little or no profit to price, that reading is a screen result rather than a bargain signal. For a pre-revenue or loss-making company the factor leans on book value and sales, and the share price mostly reflects the market's view of future outcomes, not today's fundamentals. With earnings negative, the read leans on sales, where the stock trades on about 23.6 times revenue.

Multiples

Price / earnings –
Forward P / E –
PEG ratio 0.72
Price / book –
Price / sales 23.62x
Price / free cash flow –
EV / sales –
Enterprise value –

Size & income

Market cap A$140m
Shares outstanding 600.42m
Dividend yield –
Dividend / share –
52W range A$0.16 to A$0.67
Growth
99.2
Elite

The Alpha360 growth score reads the multi-year trajectory of revenue, earnings and cash flow, rewarding durable compounding over one-off jumps. Revenue, earnings and cash flow have been expanding quickly, which is what you want from a business that is scaling. Growth off a small base can be lumpy, so the real question is how durable it proves. That trajectory is anchored by three-year revenue growth of 1,256%.

Growth rates (3yr)

Revenue growth 1,256.35%
Net income growth –
Operating cash flow growth –
Market cap growth 47.36%
Capital Market Performance
32.4
Weak

The Alpha360 capital-market score measures the shares' price strength and momentum against the market. The shares have lagged the market with poor momentum, which can flag either a value opportunity or a business the market has turned against. Over the past year the shares are down 56.0%.

Price & momentum

Annual stock return -55.96%
Stock return (6m) -54.29%
Beta 1.59
10-day volume vs avg 0.37x
52W range A$0.16 to A$0.67
Financial Strength
90.5
Very strong

The Alpha360 financial-strength score stress-tests the balance sheet, its leverage, liquidity and capacity to fund itself. The balance sheet is in good shape: modest debt, healthy liquidity and enough of a buffer to fund operations or ride out a downturn without leaning on capital markets. It runs a current ratio of 3.26 and more cash on hand than total debt.

Leverage & liquidity

Debt / equity 0.73
Current ratio 3.26
Quick ratio 3.26
Net debt / EBITDA –
Total debt / assets 0.00%
Cash flow / debt 400.62
Interest coverage –
Market cap / liabilities 1.96
Distress risk (JDS) 88.5 (Very Strong)

Cash runway

Cash runway 62 mo
Monthly cash burn A$1.10m

Balance sheet

Revenue A$5.91m
Total assets A$91.18m
Total equity A$13.38m
Total liabilities A$77.80m
Total debt A$97.48k
Net debt -A$68.19m
Cash & equivalents A$68.28m
Working capital A$50.02m
R&D expense A$32.36m
SG&A expense A$36.92m
Earnings Performance
72.2
Strong

The Alpha360 earnings score grades the quality, consistency and margin of profit, not just its headline size. Earnings are high quality and consistent, with healthy margins, so the profits are dependable rather than one-off.

Margins

Gross margin –
EBIT margin -524.31%
EBITDA margin -522.22%
Operating margin -524.31%
Net profit margin -224.08%

Quality & returns

Return on equity –
Return on assets -58.27%
Earnings stability –
EPS surprise –
Operating Efficiency
40.6
Weak

The Alpha360 efficiency score measures how much profit the business earns on each dollar of capital and revenue. The business earns poor returns on the capital invested in it, so it is not using its asset base efficiently right now. Return on assets comes in at -58.3%.

Returns on capital

Return on equity –
Return on assets -58.27%
Return on capital employed –
Return on invested capital –
EBIT / total assets -34.01%

Operating margins

Operating margin -524.31%
EBIT margin -524.31%
Cash flow margin -221.99%
Cash Flow Performance
78.0
Strong

The Alpha360 cash-flow score gauges the strength and durability of the cash the business actually generates. The business throws off strong, durable cash flow, enough to fund growth, dividends or buybacks without relying on outside capital. Cash flow returns come in at 42.8%.

Cash generation

Cash flow returns 42.83%
Free cash flow -A$13.15m
Free cash flow / share A$-0.02
Operating cash flow / share –
Cash flow margin -221.99%
Capital expenditure -A$21.01k

Coverage

Op cash flow growth (3yr) –
Cash flow / debt 400.62
The method

Every score on this page comes from Alpha360, the eight-factor model built by Professor Stewart Jones from three decades of published academic research, rescored weekly across more than 50,000 listed companies worldwide.

The research behind Alpha360 → Understand the scores → How Alpha360 works →
JDS vs. Biotechnology Peers
Ranks 3 of 40 in Biotechnology · ASX rank 104 of 1,755

This stock   Financial Trends Australia covered   Universe

More Biotechnology coverage Telix Pharmaceuticals Ltd →

Filings & Announcements

Questions

Common questions about DXB

What is Dimerix Ltd's Jones Dynamic Score?
Dimerix Ltd currently scores 82.9 (Very Strong) on the Jones Dynamic Score, ranking 3 of 12 in Biotechnology. The score is recalculated weekly from institutional-grade data.
Is DXB profitable?
Not at the net line on the latest data: Dimerix Ltd reports a net profit margin of -224.1%.
How does DXB compare to its peers?
Ranked by the Jones Dynamic Score, Dimerix Ltd sits 3 of 12 in its Biotechnology peer group. The full peer ranking, with each peer's score, is shown on this page.
Is this personal financial advice?
No. Everything on this page is general information only. It does not take into account your objectives, financial situation or needs, and you should consider whether it is appropriate for you before acting on it. The full General Advice Warning is at the bottom of this page.
What does it cost to see your rating on Dimerix Ltd?
Nothing. Enter your details in the form on this page and our current rating unlocks instantly, along with a free one-on-one walkthrough of the research with our team if you want it. The full written research note is part of membership.
Who builds the scores?
The Jones Dynamic Score and the Alpha360 factor model were built in-house from three decades of academic research. The system scores companies across global markets and is refreshed weekly.
Go deeper

Book a free walkthrough

Fifteen minutes, one on one with our research team: how the scores work, what they say about Dimerix Ltd, and what members get. No cost, no obligation.

Book a walkthrough

The full research note

Members get the complete written research note from the Financial Trends Australia analysts. Information only, not personal financial advice, and no performance is promised.

Become a member

Want our call on another stock?

Tell us the ticker or company name and we will point you to our research, or let you know when its page is live.

General Advice Warning. The information provided by Financial Trends Australia is general in nature and does not take into account your personal objectives, financial situation or needs. It does not constitute personal financial advice. Before acting on any information, you should consider its appropriateness having regard to your own objectives, financial situation and needs, and seek independent professional advice. Where the information relates to a financial product, you should obtain and consider the relevant Product Disclosure Statement (PDS) or offer document before deciding to acquire the product. Past performance is not a reliable indicator of future performance. Financial Trends Australia Pty Ltd (ABN 65 091 191 472) is a Corporate Authorised Representative (AR No. 001320926) of MF & Co. Asset Management Pty Ltd (AFSL No. 520442).